Studies have recorded a limited number of undesirable outcomes associated with SGLT-2 inhibitors, including hypoglycaemia, infections in the genital and urinary tract, fungal infections in the genital area, hypersensitive skin reactions, reduced blood volume, painful urination and diabetic ketoacidosis.58 Bexagliflozin was shown to be well tolerated, and it presented an acceptable safety profile with minimal adverse effects and a low risk of hypoglycaemia. The gene discussed is SLC5A2; the disease is Hypoglycemia.